Gazya as a New Option for Lupus Nephritis
The American College of Rheumatology (ACR) updated its lupus nephritis (LN) treatment guidelines, emphasizing triple therapy with Benlysta or...
NeuroSigma’s Monarch eTNS System ADHD Trial for Children with Fetal Alcohol Syndrome at UCLA
NeuroSigma, Inc. announced a new clinical trial for its Monarch external Trigeminal Nerve Stimulation (eTNS) device. The trial will...
Oncocyte’s Promising Clinical Trial Update
Oncocyte Corporation (Nasdaq: OCX) is preparing to launch a pivotal clinical trial for its organ transplant rejection monitoring test...
ABIVAX Completes Enrollment for Phase 3 Ulcerative Colitis Trial
Abivax completed enrollment for its Phase 3 ABTECT trials of obefazimod, a treatment for moderately to severely active ulcerative...
Oncocyte’s Assay Demonstrates Clinical Validity
Oncocyte Corporation announced positive data from a four-year study at Charité University in Berlin, validating its blood-based transplant rejection...
Incyclix Bio’s INX-315 Gets FDA Fast Track for Ovarian Cancer
Incyclix Bio‘s CDK2 inhibitor, INX-315, has received FDA Fast Track designation for treating CCNE1-amplified, platinum-resistant/refractory ovarian cancer. This designation...
New Data at AACR Meeting Highlights DecisionDx-Melanoma
Castle Biosciences presented new research on cutaneous and uveal melanoma (CM and UM) at the 2025 American Association for...
Myriad Genetics Presents MRD Data at AACR Meeting
Myriad Genetics presented clinical data at the American Association for Cancer Research (AACR) Annual Meeting showcasing the performance of...
Promising Preclinical Results for Micvotabart Pelidotin
Pyxis Oncology revealed promising preclinical data for its lead antibody-drug conjugate, micvotabart pelidotin (MICVO), at the 2025 American Association...
Evorpacept Shows Encouraging Results in B-Cell Lymphoma Trial
ALX Oncology’s investigational CD47-blocker, evorpacept, combined with rituximab and lenalidomide (R2), showed promising results in a Phase 1/2 trial...